{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:28:09Z","timestamp":1772609289803,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pemafibrate helps regulate fatty acid dynamics in the liver, potentially preventing metabolic dysfunction-associated steatohepatitis (MASH). However, its effect on intestinal long-chain fatty acid (LCFA) metabolism in MASH remains unclear. Thus, we aimed to examine the influence of pemafibrate on intestinal LCFA metabolism and hepatic fibrosis in a MASH rat model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Sprague\u2013Dawley rats were fed a high-fat and high-cholesterol diet to induce MASH and then divided into pemafibrate-treated (pemafibrate (+)) and untreated (pemafibrate (-)) groups. Triglyceride deposition in the small intestine and fibrosis, along with \u03b1-smooth muscle actin level in the liver, were evaluated. Furthermore, the mRNA expression levels of genes associated with lipid metabolism in the small intestine and markers of fibrosis and hepatic stellate cells activation in the liver were measured.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The pemafibrate-treated group had markedly lower triglyceride deposition and lipid absorption in the intestine, and significantly lower levels of molecules involved in intestinal lipid regulation than the pemafibrate-untreated group. Moreover, hepatic fibrosis significantly improved, and the mRNA levels of fibrosis-related molecules and hepatic stellate cell activation factors significantly decreased in the pemafibrate-treated compared with those in the pemafibrate-untreated group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Pemafibrate reduced lipid droplet formation and LCFA absorption in the intestinal tract and alleviated hepatic fibrosis in MASH model rats.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12876-025-03967-z","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:21:16Z","timestamp":1747657276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of pemafibrate in reducing intestinal long-chain fatty acid absorption and hepatic fibrosis in metabolic dysfunction-associated steatohepatitis rats"],"prefix":"10.1186","volume":"25","author":[{"given":"Masaya","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Hanayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"3967_CR1","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/hep.28123","volume":"62","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the united States from 2004 to 2009. Hepatology. 2015;62:1723\u201330.","journal-title":"Hepatology"},{"key":"3967_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"3967_CR3","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1185\/03007995.2010.506375","volume":"26","author":"A Sanyal","year":"2010","unstructured":"Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010;26:2183\u201391.","journal-title":"Curr Med Res Opin"},{"key":"3967_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686\u201390.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3967_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113\u201321.","journal-title":"Gastroenterology"},{"key":"3967_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333.","journal-title":"Hepatology"},{"key":"3967_CR7","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","volume":"23","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263\u201376.","journal-title":"World J Gastroenterol"},{"key":"3967_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hep.20283","volume":"40","author":"AE Feldstein","year":"2004","unstructured":"Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40:185\u201394.","journal-title":"Hepatology"},{"key":"3967_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/hep.21752","volume":"46","author":"S Joshi-Barve","year":"2007","unstructured":"Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, et al. Palmitic acid induces production of Proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology. 2007;46:823\u201330.","journal-title":"Hepatology"},{"key":"3967_CR10","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1194\/jlr.R066357","volume":"57","author":"P Hirsova","year":"2016","unstructured":"Hirsova P, Ibrabim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res. 2016;57:1758\u201370.","journal-title":"J Lipid Res"},{"key":"3967_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev-nutr-071816-064836","volume":"37","author":"JC Ralston","year":"2017","unstructured":"Ralston JC, Lyons CL, Kennedy EB, Kirwan AM, Roche HM. Fatty acids and NLRP3 inflammasome-mediated inflammation in metabolic tissues. Annu Rev Nutr. 2017;37:77\u2013102.","journal-title":"Annu Rev Nutr"},{"key":"3967_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1172\/JCI34275","volume":"118","author":"C Postic","year":"2008","unstructured":"Postic C, Girard J. Contribution of de Novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118:829\u201338.","journal-title":"J Clin Invest"},{"key":"3967_CR13","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s00535-016-1298-6","volume":"52","author":"H Utsunomiya","year":"2017","unstructured":"Utsunomiya H, Yamamoto Y, Takeshita E, Tokumoto Y, Tada F, Miyake T, et al. Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH). J Gastroenterol. 2017;52:940\u201354.","journal-title":"J Gastroenterol"},{"key":"3967_CR14","doi-asserted-by":"publisher","first-page":"13380","DOI":"10.1038\/s41598-021-92790-z","volume":"11","author":"M Hanayama","year":"2021","unstructured":"Hanayama M, Yamamoto Y, Utsunomiya H, Yoshida O, Liu S, Mogi M, et al. The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis. Sci Rep. 2021;11:13380.","journal-title":"Sci Rep"},{"key":"3967_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","volume":"13","author":"B Gross","year":"2017","unstructured":"Gross B, Pawlak M, Lefebvre P, Staels B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol. 2017;13:36\u201349.","journal-title":"Nat Rev Endocrinol"},{"key":"3967_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bbalip.2010.12.011","volume":"1811","author":"A Uchida","year":"2011","unstructured":"Uchida A, Slipchenko MN, Cheng JX, Buhman KK. Fenofibrate, a peroxisome proliferator-activated receptor \u03b1 agonist, alters triglyceride metabolism in enterocytes of mice. Biochim Biophys Acta. 2011;1811:170\u20136.","journal-title":"Biochim Biophys Acta"},{"key":"3967_CR17","doi-asserted-by":"publisher","first-page":"7355","DOI":"10.1073\/pnas.91.15.7355","volume":"91","author":"SA Kliewer","year":"1994","unstructured":"Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994;91:7355\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3967_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endo.137.1.8536636","volume":"137","author":"O Braissant","year":"1996","unstructured":"Braissant O, Foufelle F, Scotto C, Dau\u00e7a M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137:354\u201366.","journal-title":"Endocrinology"},{"key":"3967_CR19","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.2337\/diabetes.50.12.2809","volume":"50","author":"M Guerre-Millo","year":"2001","unstructured":"Guerre-Millo M, Rouault C, Poulain P, Andr\u00e9 J, Poitout V, Peters JM, et al. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes. 2001;50:2809\u201314.","journal-title":"Diabetes"},{"key":"3967_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature01921","volume":"425","author":"J Fu","year":"2003","unstructured":"Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, De Rodr\u00edguez F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425:90\u20133.","journal-title":"Nature"},{"key":"3967_CR21","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1093\/eurheartj\/ehs227","volume":"34","author":"S Colin","year":"2013","unstructured":"Colin S, Briand O, Touche V, Wouters K, Baron M, Pattou F, et al. Activation of intestinal peroxisome proliferator-activated receptor-\u03b1 increases high-density lipoprotein production. Eur Heart J. 2013;34:2566\u201374.","journal-title":"Eur Heart J"},{"key":"3967_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMp1106688","volume":"365","author":"AB Goldfine","year":"2011","unstructured":"Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemias\u2013time for a reassessment. N Engl J Med. 2011;365:481\u20134.","journal-title":"N Engl J Med"},{"key":"3967_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1475-2840-12-82","volume":"12","author":"JC Fruchart","year":"2013","unstructured":"Fruchart JC. Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists. Cardiovasc Diabetol. 2013;12:82.","journal-title":"Cardiovasc Diabetol"},{"key":"3967_CR24","doi-asserted-by":"publisher","first-page":"42477","DOI":"10.1038\/srep42477","volume":"7","author":"Y Honda","year":"2017","unstructured":"Honda Y, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Fujita K, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017;7:42477.","journal-title":"Sci Rep"},{"key":"3967_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jnutbio.2016.10.007","volume":"40","author":"M Ichimura","year":"2017","unstructured":"Ichimura M, Masuzumi M, Kawase M, Sakaki M, Tamaru S, Nagata Y, et al. A diet-induced Sprague-Dawley rat model of nonalcoholic steatohepatitis-related cirrhosis. J Nutr Biochem. 2017;40:62\u20139.","journal-title":"J Nutr Biochem"},{"key":"3967_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-nutr-071812-161220","volume":"34","author":"MY Pepino","year":"2014","unstructured":"Pepino MY, Kuda O, Samovski D, Abumrad NA. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr. 2014;34:281\u2013303.","journal-title":"Annu Rev Nutr"},{"key":"3967_CR27","doi-asserted-by":"publisher","first-page":"33047","DOI":"10.1074\/jbc.271.51.33047","volume":"271","author":"DA Gordon","year":"1996","unstructured":"Gordon DA, Jamil H, Gregg RE, Olofsson SO, Bor\u00e9n J. Inhibition of the microsomal triglyceride transfer protein blocks the first step of Apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step. J Biol Chem. 1996;271:33047\u201353.","journal-title":"J Biol Chem"},{"key":"3967_CR28","doi-asserted-by":"publisher","first-page":"12272","DOI":"10.1074\/jbc.272.19.12272","volume":"272","author":"Y Wang","year":"1997","unstructured":"Wang Y, McLeod RS, Yao Z. Normal activity of microsomal triglyceride transfer protein is required for the oleate-induced secretion of very low density lipoproteins containing Apolipoprotein B from McA-RH7777 cells. J Biol Chem. 1997;272:12272\u20138.","journal-title":"J Biol Chem"},{"key":"3967_CR29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jnutbio.2010.01.005","volume":"21","author":"BP Atshaves","year":"2010","unstructured":"Atshaves BP, Martin GG, Hostetler HA, McIntosh AL, Kier AB, Schroeder F. Liver fatty acid-binding protein and obesity. J Nutr Biochem. 2010;21:1015\u201332.","journal-title":"J Nutr Biochem"},{"key":"3967_CR30","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1242\/jcs.03280","volume":"119","author":"K Milger","year":"2006","unstructured":"Milger K, Herrmann T, Becker C, Gotthardt D, Zickwolf J, Ehehalt R, et al. Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4. J Cell Sci. 2006;119:4678\u201388.","journal-title":"J Cell Sci"},{"key":"3967_CR31","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cells8111419","volume":"8","author":"B Dewidar","year":"2019","unstructured":"Dewidar B, Meyer C, Dooley S, Meindl-Beinker AN. TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells. 2019;8:1419.","journal-title":"Cells"},{"key":"3967_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-2001-17556","volume":"21","author":"D Schuppan","year":"2001","unstructured":"Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis. 2001;21:351\u201372.","journal-title":"Semin Liver Dis"},{"key":"3967_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jcp.22783","volume":"227","author":"AK Ghosh","year":"2012","unstructured":"Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol. 2012;227:493\u2013507.","journal-title":"J Cell Physiol"},{"key":"3967_CR34","doi-asserted-by":"publisher","first-page":"e0146337","DOI":"10.1371\/journal.pone.0146337","volume":"11","author":"Y Honda","year":"2016","unstructured":"Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, et al. The selective SGLT2 inhibitor Ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS ONE. 2016;11:e0146337.","journal-title":"PLoS ONE"},{"key":"3967_CR35","doi-asserted-by":"publisher","first-page":"166215","DOI":"10.1016\/j.bbadis.2021.166215","volume":"1867","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Kamisako T. Regulation of the expression of cholesterol transporters by lipid-lowering drugs Ezetimibe and pemafibrate in rat liver and intestine. Biochim Biophys Acta Mol Basis Dis. 2021;1867:166215.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3967_CR36","doi-asserted-by":"publisher","first-page":"32345","DOI":"10.1074\/jbc.M313478200","volume":"279","author":"VT Samuel","year":"2004","unstructured":"Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345\u201353.","journal-title":"J Biol Chem"},{"key":"3967_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/hep.1840030312","volume":"3","author":"A Avgerinos","year":"1983","unstructured":"Avgerinos A, Chu P, Greenfield C, Harry DS, McIntyre N. Plasma lipid and lipoprotein response to fat feeding in alcoholic liver disease. Hepatology. 1983;3:349\u201355.","journal-title":"Hepatology"},{"key":"3967_CR38","doi-asserted-by":"publisher","first-page":"612089","DOI":"10.1155\/2010\/612089","volume":"2010","author":"M Rakhshandehroo","year":"2010","unstructured":"Rakhshandehroo M, Knoch B, M\u00fcller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010;2010:612089.","journal-title":"PPAR Res"},{"key":"3967_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jphs.2017.02.003","volume":"133","author":"K Takei","year":"2017","unstructured":"Takei K, Nakagawa Y, Wang Y, Han SI, Satoh A, Sekiya M, et al. Effects of K-877, a novel selective PPAR\u03b1 modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice. J Pharmacol Sci. 2017;133:214\u201322.","journal-title":"J Pharmacol Sci"},{"key":"3967_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/hep.32538","volume":"77","author":"T Yan","year":"2023","unstructured":"Yan T, Luo Y, Yan N, Hamada K, Zhao N, Xia Y, et al. Intestinal peroxisome proliferator-activated receptor \u03b1-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis. Hepatology. 2023;77:239\u201355.","journal-title":"Hepatology"},{"key":"3967_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1152\/physrev.00013.2007","volume":"88","author":"SL Friedman","year":"2008","unstructured":"Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125\u201372.","journal-title":"Physiol Rev"},{"key":"3967_CR42","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","volume":"68","author":"F Marra","year":"2018","unstructured":"Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280\u201395.","journal-title":"J Hepatol"},{"key":"3967_CR43","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","volume":"73","author":"H Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Moschen AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade. Hepatology. 2021;73:833\u201342.","journal-title":"Hepatology"},{"key":"3967_CR44","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/apt.16596","volume":"54","author":"A Nakajima","year":"2021","unstructured":"Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, et al. Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54:1263\u201377.","journal-title":"Aliment Pharmacol Ther"},{"key":"3967_CR45","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.3390\/ijms19072148","volume":"19","author":"M Araki","year":"2018","unstructured":"Araki M, Nakagawa Y, Oishi A, Han SI, Wang Y, Kumagai K, et al. The peroxisome Proliferator-Activated receptor \u03b1 (PPAR\u03b1) agonist pemafibrate protects against Diet-Induced obesity in mice. Int J Mol Sci. 2018;19:2148.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03967-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03967-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03967-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:03:37Z","timestamp":1747659817000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03967-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3967"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03967-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in strict accordance with the recommendations in the guidelines of Ehime University (Ehime, Japan). The protocol was approved by the Ehime University Animal Care Committee (Protocol Number: 05-TI-86-2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"385"}}